Ludwig Center at Harvard
The Ludwig Center at Harvard Medical School brings together investigators from across Harvard to develop strategies to overcome barriers that limit the efficacy of current and emerging cancer therapies.
Explore
- Learn about Ludwig Center at Harvard
- Meet our Team
- Explore our Science
Featured Publications
2026
Lee, Y. S. et al. Synergistic targeting of eIF4A-mediated translation initiation and apoptosis in acute myeloid leukemia. Blood neoplasia 3, 100202 (2026).
Lee, Y. S. et al. Synergistic targeting of eIF4A-mediated translation initiation and apoptosis in acute myeloid leukemia. Blood neoplasia 3, 100202 (2026).
Wu, B. et al. TROP2/claudin program mediates immune exclusion to impede checkpoint blockade in breast cancer. Journal for immunotherapy of cancer 14, (2026).
Wu, B. et al. TROP2/claudin program mediates immune exclusion to impede checkpoint blockade in breast cancer. Journal for immunotherapy of cancer 14, (2026).
Goyette, M.-A. et al. HER2 heterogeneous breast cancer models reveal novel therapeutic targets and subclonal dynamics during evolution to resistance to HER2-targeted therapies. Cancer discovery (2026) doi:10.1158/2159-8290.CD-25-1459.
Goyette, M.-A. et al. HER2 heterogeneous breast cancer models reveal novel therapeutic targets and subclonal dynamics during evolution to resistance to HER2-targeted therapies. Cancer discovery (2026) doi:10.1158/2159-8290.CD-25-1459.
Lee, S. M. et al. Host microRNA-31-5p regulates KHDRBS3 expression and modulates viral gene expression during KSHV lytic reactivation. Cell reports 45, 117160 (2026).
Lee, S. M. et al. Host microRNA-31-5p regulates KHDRBS3 expression and modulates viral gene expression during KSHV lytic reactivation. Cell reports 45, 117160 (2026).
Meylan, M. et al. Persistent T cell activation and cytotoxicity against glioblastoma following single oncolytic virus treatment in a clinical trial. Cell 189, 1287–1304.e18 (2026).
Meylan, M. et al. Persistent T cell activation and cytotoxicity against glioblastoma following single oncolytic virus treatment in a clinical trial. Cell 189, 1287–1304.e18 (2026).